Abstract:

Major Depressant Disorder is one of the most common neuropsychiatric disorders and affects 17-20% of the world population. Despite scientific efforts, its treatment still presents itself with a limited efficacy and a delayed start-up effect. In this context, natural products are a potential source of new drugs. Riparin I (Rip I), one alcamide isolated from Aniba Riparia, has presented promising results. In pre-clinic trials, it has unchained predictive effects of antidepressant and anxiolytic activities in acute behavioral models of depression and anxiety.